title: Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study.
abstract: Rationale and design of a study on the cost-effectiveness of the Dutch influenza vaccination campaign are described. During two influenza epidemics, about 75,000 primary care patients recommended for influenza vaccination are included. Cases have fatal or non-fatal influenza, pneumonia, otitis media, acute respiratory disease (ARD), heart failure, myocardial infarction, depression or diabetes dysregulation. Per case four controls are sampled, frequency matched on age and high-risk co-morbidity (<18 years, 18-64, >/=65 healthy, >/=65 with co-morbidity). Baseline and outcome data are retrieved from patient records. During the 1999-2000 influenza A epidemic 5891 (7.9%) high-risk children, 24,848 (33.2%) high-risk adults aged 18-64 years, 18,484 (24.7%) elderly with co-morbidity and 25,527 (34.1%) healthy elderly had been included. The mortality rate was 5.2 per 1000 and 2035 non-fatal outcome events were recorded (incidence rate 27.2/1000).
authors.affiliation: Julius Center for Health Sciences and Primary Care, P.O. Box 85060, 3508 AB, Utrecht, The Netherlands. e.hak@med.uu.nl
authors.forename: E
authors.initials: E
authors.lastname: Hak
authors.forename: S
authors.initials: S
authors.lastname: van Loon
authors.forename: E
authors.initials: E
authors.lastname: Buskens
authors.forename: G A
authors.initials: GA
authors.lastname: van Essen
authors.forename: D
authors.initials: D
authors.lastname: de Bakker
authors.forename: M A J B
authors.initials: MA
authors.lastname: Tacken
authors.forename: B A
authors.initials: BA
authors.lastname: van Hout
authors.forename: D E
authors.initials: DE
authors.lastname: Grobbee
authors.forename: Th J M
authors.initials: TJ
authors.lastname: Verheij
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D007223:Infant; D007231:Infant, Newborn; D007252:Influenza Vaccines / Q000191:economics / Q000627:therapeutic use; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D016015:Logistic Models; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D016017:Odds Ratio; D011159:Population Surveillance / Q000379:methods*
chemical_list: D007252:Influenza Vaccines